Clinical Trial Update: Hydralazine as a Demethylating Agent in Rectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 trial evaluating hydralazine as a demethylating agent for rectal cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Hydralazine (hydralazine)

Snippet

Sponsor: University of Arkansas | Conditions: Rectal Cancer | Phase 1, Phase 2 | Status: WITHDRAWN